Molecular imaging of cell transplantation in Parkinson’s disease

Editorial commentary
  • 69 Downloads

References

  1. 1.
    Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283–2301PubMedCrossRefGoogle Scholar
  2. 2.
    Lindvall O, Bjorklund A. Cell therapy in Parkinson’s disease. NeuroRx 2004;1:382–393PubMedCrossRefGoogle Scholar
  3. 3.
    Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson’s disease: how can we make it work? Trends Neurosci 2005;28:86–92PubMedCrossRefGoogle Scholar
  4. 4.
    Bjorklund A, Dunnett SB, Brundin P, Stoessl AJ, Freed CR, Breeze RE, et al. Neural transplantation for the treatment of Parkinson’s disease. Lancet Neurol 2003;2:437–445PubMedCrossRefGoogle Scholar
  5. 5.
    Redmond DE Jr. Cellular replacement therapy for Parkinson’s disease—where we are today? Neuroscientist 2002;8:457–488PubMedCrossRefGoogle Scholar
  6. 6.
    Kordower JH, Rosenstein JM, Collier TJ, Burke MA, Chen EY, Li JM, et al. Functional fetal nigral grafts in a patient with Parkinson’s disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 1996;370:203–230PubMedCrossRefGoogle Scholar
  7. 7.
    Rauch RA, Markham CH, Rand RW, Becker DP, Lufkin RB. MR imaging findings after transplant surgery for Parkinson disease. J Magn Reson Imaging 1994;4:19–24PubMedCrossRefGoogle Scholar
  8. 8.
    Ross BD, Hoang TQ, Bluml S, Dubowitz D, Kopyov OV, Jacques DB, et al. In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed 1999; 12: 221–236PubMedCrossRefGoogle Scholar
  9. 9.
    Brooks DJ. Positron emission tomography imaging of transplant function. NeuroRx 2004;1:482–491PubMedCrossRefGoogle Scholar
  10. 10.
    Pogarell O, Koch W, Gildehaus FJ, Kupsch A, Lindvall O, Oertel WH, et al. Long-term assessment of striatal dopamine transporters in parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (in press). DOI 10.1007/s00259-005-0032-zGoogle Scholar
  11. 11.
    Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson’s disease. Exp Neurol 2003;184:S68–S79PubMedCrossRefGoogle Scholar
  12. 12.
    Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 2005;128:2777–2785PubMedCrossRefGoogle Scholar
  13. 13.
    Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. PET and SPECT functional imaging studies in parkinsonian syndromes: from the lesion to its consequences. Neuroimage 2004;23:1–16PubMedCrossRefGoogle Scholar
  14. 14.
    Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS. Striatal function in normal aging: implications for Parkinson’s disease. Ann Neurol 1990;28:799–804PubMedCrossRefGoogle Scholar
  15. 15.
    Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577–583PubMedCrossRefGoogle Scholar
  16. 16.
    Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, et al. Presynaptic monoaminergic vesicles in Parkinson’s disease and normal aging. Ann Neurol 1996;40:873–884PubMedCrossRefGoogle Scholar
  17. 17.
    Kilbourn MR, Frey KA, Vander Borght T, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol 1996;23:467–471PubMedCrossRefGoogle Scholar
  18. 18.
    Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996;16: 3507–3510PubMedGoogle Scholar
  19. 19.
    Guilarte TR, Nihei MK, McGlothan JL, Howard AS. Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 2003;122:499–513PubMedCrossRefGoogle Scholar
  20. 20.
    Naudon L, Raisman-Vozari R, Edwards RH, Leroux-Nicollet I, Peter D, Liu Y, et al. Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites. Eur J Neurosci 1996;8:842–846PubMedCrossRefGoogle Scholar
  21. 21.
    Brown JM, Hanson GR, Fleckenstein AE. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther 2001;296:762–767PubMedGoogle Scholar
  22. 22.
    Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE , et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol 2000;47:493–503PubMedCrossRefGoogle Scholar
  23. 23.
    Ribeiro MJ, Vidailhet M, Loc'h C, Dupel C, Nguyen JP, Ponchant M, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol 2002;59:580–586PubMedCrossRefGoogle Scholar
  24. 24.
    Cochen V, Ribeiro MJ, Nguyen JP, Gurruchaga JM, Villafane G, Loc'h C, et al. Transplantation in Parkinson’s disease: PET changes correlate with the amount of grafted tissue. Mov Disord 2003;18:928–932PubMedCrossRefGoogle Scholar
  25. 25.
    Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF, et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 1995;38:580–588PubMedCrossRefGoogle Scholar
  26. 26.
    Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R, et al. Delayed recovery of movement-related cortical function in Parkinson’s disease after striatal dopaminergic grafts. Ann Neurol 2000;48:689–695PubMedCrossRefGoogle Scholar
  27. 27.
    Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient. Nat Neurosci 1999;2:1137–1140PubMedCrossRefGoogle Scholar
  28. 28.
    Andringa G, Drukarch B, Bol JG, de BK, Sorman K, Habraken JB, et al. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson’s disease. Neuroimage 2005;26:1150–1158PubMedCrossRefGoogle Scholar
  29. 29.
    Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 2005;57:168–175PubMedCrossRefGoogle Scholar
  30. 30.
    Grafton ST. Contributions of functional imaging to understanding parkinsonian symptoms. Curr Opin Neurobiol 2004;14:715–719PubMedCrossRefGoogle Scholar
  31. 31.
    Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson’s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003;60:601–605PubMedGoogle Scholar
  32. 32.
    Boucai L, Cerquetti D, Merello M. Functional surgery for Parkinson’s disease treatment: a structured analysis of a decade of published literature. Br J Neurosurg 2004;18:213–222PubMedCrossRefGoogle Scholar
  33. 33.
    Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol 2001;60:741–752PubMedGoogle Scholar
  34. 34.
    Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson’s disease. Trends Neurosci 1996;19:102–109PubMedCrossRefGoogle Scholar
  35. 35.
    Sortwell CE. Strategies for the augmentation of grafted dopamine neuron survival. Front Biosci 2003;8:s522–s532PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Nuclear Medicine Division, Mont-Godinne Medical CenterUniversité Catholique de LouvainYvoirBelgium

Personalised recommendations